| 2018 | | P1.15-14: Pneumonia in Patients with Lung Cancer of South Korea: A Nationwide Population Based Study | 이현우, 정준호, 허재성 |
| 2023 | | p15INK4B is an alternative marker of senescent tumor cells in colorectal cancer | 김영화, 김장희, 박태준, 신준상, 이영경, 임수빈, 최용원 |
| 2018 | | P2.12-01: Efficacy of Belotecan as Second-Line Treatment for Recurrent Small Cell Lung Cancer: A Phase IIb Randomized Multicenter Study | 최진혁 |
| 2019 | | Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial | 강석윤 |
| 1995 | | Patency of a small vessel prosthesis bonded to tissue plasminogen activator and iloprost. | 김효철 |
| 2012 | | Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases | 김보영, 김세혁, 김영배, 김장희, 신승수, 이기범, 이현우, 정선용, 한재호 |
| 2018 | | Patient's Cognitive Function and Attitudes towards Family Involvement in Cancer Treatment Decision Making: A Patient-Family Caregiver Dyadic Analysis | 이현우 |
| 2020 | | Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10) | 강석윤 |
| 2014 | | Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. | 강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2019 | | PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data | 고영화, 이수진, 이현우, 정준호, 한재호, 함석진 |
| 2022 | | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study | 정성현, 최윤석 |
| 2019 | | Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY) | 강석윤 |
| 2022 | | Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy | 권민석 |
| 2021 | | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study) | 강석윤 |
| 2020 | | Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07 | 안미선 |
| 2019 | | Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study | 정성현 |
| 2022 | | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) | 안미선 |
| 2016 | | Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008) | 정성현 |
| 2015 | | Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). | 안미선 |
| 2012 | | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study | 김효철 |
